Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358734 · ClinicalTrials.gov registry record · Phase 2
A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia
A Phase 2 study, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 88
- Enrollment target
NCT01358734 is a Phase 2 study that has completed, run by Celgene. The registered enrollment target is 88 participants.
The verdict
NCT01358734, a Phase 2 study, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 88 participants
- Enrollment target
Study Summary
The study aim is to compare safety and efficacy of high-dose lenalidomide regimen, sequential azacitidine and lenalidomide and an azacitidine in persons ≥65 years with newly-diagnosed acute myeloid leukemia (AML).
Interventions
- DRUG Azacitidine
- DRUG Lenalidomide
- OTHER Best Supportive Care (BSC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2012-04-27 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358734
The ClinicalTrials.gov registry entry for NCT01358734 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Azacitidine is the first listed.
NCT01358734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01358734 about?
NCT01358734 is a clinical study titled "A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia". The study aim is to compare safety and efficacy of high-dose lenalidomide regimen, sequential azacitidine and lenalidomide and an azacitidine in persons ≥65 years with newly-diagnosed acute myeloid leukemia (AML).
What is the current status of trial NCT01358734?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 88 participants. The study started on 2012-04-27. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT01358734?
The interventions under investigation include: Azacitidine (DRUG), Lenalidomide (DRUG), Best Supportive Care (BSC) (OTHER).
Who is sponsoring clinical trial NCT01358734?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.